These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22523595)

  • 1. A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
    Uboldi S; Calura E; Beltrame L; Fuso Nerini I; Marchini S; Cavalieri D; Erba E; Chiorino G; Ostano P; D'Angelo D; D'Incalci M; Romualdi C
    PLoS One; 2012; 7(4):e35423. PubMed ID: 22523595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
    Uboldi S; Bernasconi S; Romano M; Marchini S; Fuso Nerini I; Damia G; Ganzinelli M; Marangon E; Sala F; Clivio L; Chiorino G; Di Giandomenico S; Rocchi M; Capozzi O; Margison GP; Watson AJ; Caccuri AM; Pastore A; Fossati A; Mantovani R; Grosso F; Tercero JC; Erba E; D'Incalci M
    Int J Cancer; 2012 Jul; 131(1):59-69. PubMed ID: 21805478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
    Grosso F; Jones RL; Demetri GD; Judson IR; Blay JY; Le Cesne A; Sanfilippo R; Casieri P; Collini P; Dileo P; Spreafico C; Stacchiotti S; Tamborini E; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Fletcher JA; Pilotti S; Casali PG
    Lancet Oncol; 2007 Jul; 8(7):595-602. PubMed ID: 17586092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.
    Frapolli R; Tamborini E; Virdis E; Bello E; Tarantino E; Marchini S; Grosso F; Sanfilippo R; Gronchi A; Tercero JC; Peloso G; Casali P; Pilotti S; D'Incalci M
    Clin Cancer Res; 2010 Oct; 16(20):4958-67. PubMed ID: 20732964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
    D'Incalci M; Badri N; Galmarini CM; Allavena P
    Br J Cancer; 2014 Aug; 111(4):646-50. PubMed ID: 24755886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.
    Forni C; Minuzzo M; Virdis E; Tamborini E; Simone M; Tavecchio M; Erba E; Grosso F; Gronchi A; Aman P; Casali P; D'Incalci M; Pilotti S; Mantovani R
    Mol Cancer Ther; 2009 Feb; 8(2):449-57. PubMed ID: 19190116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trabectedin--a targeted chemotherapy?
    von Mehren M
    Lancet Oncol; 2007 Jul; 8(7):565-7. PubMed ID: 17613417
    [No Abstract]   [Full Text] [Related]  

  • 8. Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
    Bello E; Brich S; Craparotta I; Mannarino L; Ballabio S; Gatta R; Marchini S; Carrassa L; Matteo C; Sanfilippo R; Gronchi A; Casali PG; Pilotti S; D'Incalci M; Frapolli R
    Br J Cancer; 2019 Sep; 121(6):464-473. PubMed ID: 31409911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
    Germano G; Frapolli R; Simone M; Tavecchio M; Erba E; Pesce S; Pasqualini F; Grosso F; Sanfilippo R; Casali PG; Gronchi A; Virdis E; Tarantino E; Pilotti S; Greco A; Nebuloni M; Galmarini CM; Tercero JC; Mantovani A; D'Incalci M; Allavena P
    Cancer Res; 2010 Mar; 70(6):2235-44. PubMed ID: 20215499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The intriguing patterns of tumor response to trabectedin.
    Sanfilippo R; Casali PG
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):21-4. PubMed ID: 23638727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mode of action of trabectedin in myxoid liposarcomas.
    Di Giandomenico S; Frapolli R; Bello E; Uboldi S; Licandro SA; Marchini S; Beltrame L; Brich S; Mauro V; Tamborini E; Pilotti S; Casali PG; Grosso F; Sanfilippo R; Gronchi A; Mantovani R; Gatta R; Galmarini CM; Sousa-Faro JM; D'Incalci M
    Oncogene; 2014 Oct; 33(44):5201-10. PubMed ID: 24213580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.
    Assi T; Kattan J; El Rassy E; Honore C; Dumont S; Mir O; Le Cesne A
    Cancer Treat Rev; 2019 Jan; 72():37-44. PubMed ID: 30468937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of trabectedin for the treatment of liposarcoma.
    Zijoo R; von Mehren M
    Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete response of a recurrent-metastatic liposarcoma with dedifferentiated histological features following the administration of trabectedin and review of literature.
    Kus T; Aktas G; Kalender ME; Tutar E; Ulker E; Camci C
    J Cancer Res Ther; 2015; 11(4):974-6. PubMed ID: 26881560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.
    Gronchi A; Bui BN; Bonvalot S; Pilotti S; Ferrari S; Hohenberger P; Hohl RJ; Demetri GD; Le Cesne A; Lardelli P; Pérez I; Nieto A; Tercero JC; Alfaro V; Tamborini E; Blay JY
    Ann Oncol; 2012 Mar; 23(3):771-776. PubMed ID: 21642514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
    Grohar PJ; Griffin LB; Yeung C; Chen QR; Pommier Y; Khanna C; Khan J; Helman LJ
    Neoplasia; 2011 Feb; 13(2):145-53. PubMed ID: 21403840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.
    Dossi R; Frapolli R; Di Giandomenico S; Paracchini L; Bozzi F; Brich S; Castiglioni V; Borsotti P; Belotti D; Uboldi S; Sanfilippo R; Erba E; Giavazzi R; Marchini S; Pilotti S; D'Incalci M; Taraboletti G
    Int J Cancer; 2015 Feb; 136(3):721-9. PubMed ID: 24917554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
    Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models.
    Martinez-Cruzado L; Tornin J; Rodriguez A; Santos L; Allonca E; Fernandez-Garcia MT; Astudillo A; Garcia-Pedrero JM; Rodriguez R
    Neoplasia; 2017 Jun; 19(6):460-470. PubMed ID: 28494349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma.
    Mannarino L; Craparotta I; Ballabio S; Frapolli R; Meroni M; Bello E; Panini N; Callari M; Sanfilippo R; Casali PG; Barisella M; Fabbroni C; Marchini S; D'Incalci M
    Genomics; 2021 Sep; 113(5):3439-3448. PubMed ID: 34339817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.